linsidomine has been researched along with Parkinson Disease in 5 studies
linsidomine: RN given refers to parent cpd; structure
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We have examined potent peroxynitrite ion (ONOO-) generator 3-morpholinosydnonimine (SIN-1)-induced neurotoxicity in control wild-type (control(wt)) mice, metallothionein double knockout (MT(dko)) mice, metallothionein-transgenic (MT(trans)) mice, and in cultured human dopaminergic (SK-N-SH) neurons to determine the neuroprotective potential of metallothionein against ONOO(-)-induced neurodegeneration in Parkinson disease (PD)." | 7.73 | Metallothioneins 1 and 2 attenuate peroxynitrite-induced oxidative stress in Parkinson disease. ( Ebadi, M; Sharma, S, 2006) |
| "We have examined potent peroxynitrite ion (ONOO-) generator 3-morpholinosydnonimine (SIN-1)-induced neurotoxicity in control wild-type (control(wt)) mice, metallothionein double knockout (MT(dko)) mice, metallothionein-transgenic (MT(trans)) mice, and in cultured human dopaminergic (SK-N-SH) neurons to determine the neuroprotective potential of metallothionein against ONOO(-)-induced neurodegeneration in Parkinson disease (PD)." | 3.73 | Metallothioneins 1 and 2 attenuate peroxynitrite-induced oxidative stress in Parkinson disease. ( Ebadi, M; Sharma, S, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hung, LW | 1 |
| Villemagne, VL | 1 |
| Cheng, L | 1 |
| Sherratt, NA | 1 |
| Ayton, S | 1 |
| White, AR | 1 |
| Crouch, PJ | 1 |
| Lim, S | 1 |
| Leong, SL | 1 |
| Wilkins, S | 1 |
| George, J | 1 |
| Roberts, BR | 1 |
| Pham, CL | 1 |
| Liu, X | 1 |
| Chiu, FC | 1 |
| Shackleford, DM | 1 |
| Powell, AK | 1 |
| Masters, CL | 1 |
| Bush, AI | 1 |
| O'Keefe, G | 1 |
| Culvenor, JG | 1 |
| Cappai, R | 1 |
| Cherny, RA | 1 |
| Donnelly, PS | 1 |
| Hill, AF | 1 |
| Finkelstein, DI | 1 |
| Barnham, KJ | 1 |
| Lev, N | 1 |
| Melamed, E | 1 |
| Offen, D | 1 |
| Jiang, H | 1 |
| Wu, YC | 1 |
| Nakamura, M | 1 |
| Liang, Y | 1 |
| Tanaka, Y | 1 |
| Holmes, S | 1 |
| Dawson, VL | 1 |
| Dawson, TM | 1 |
| Ross, CA | 1 |
| Smith, WW | 1 |
| Ebadi, M | 1 |
| Sharma, S | 1 |
| Naoi, M | 1 |
| Maruyama, W | 1 |
5 other studies available for linsidomine and Parkinson Disease
| Article | Year |
|---|---|
The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Cell Line, Tumor; Cognition; Coordination Complexes; Disease Models, Anima | 2012 |
Proteasomal inhibition hypersensitizes differentiated neuroblastoma cells to oxidative damage.
Topics: alpha-Synuclein; Benzothiazoles; Cell Differentiation; Cell Line, Tumor; Cytoplasm; Ferrous Compound | 2006 |
Parkinson's disease genetic mutations increase cell susceptibility to stress: mutant alpha-synuclein enhances H2O2- and Sin-1-induced cell death.
Topics: alpha-Synuclein; Animals; Cell Death; Dose-Response Relationship, Drug; Genetic Predisposition to Di | 2007 |
Metallothioneins 1 and 2 attenuate peroxynitrite-induced oxidative stress in Parkinson disease.
Topics: Animals; Apoptosis; Caspase 3; Caspases; Coenzymes; Dopamine; Enzyme Activation; Lipid Peroxidation; | 2006 |
Future of neuroprotection in Parkinson's disease.
Topics: Apoptosis; Humans; Molsidomine; Neuroprotective Agents; Neurotoxins; Nitric Oxide Donors; Oxidopamin | 2001 |